Table 3.

Redox status of [NADH/[NAD+] in hypoxic nonreplicating Mtb H37Rv

Drug treatment (μM)NAD+, μMNADH, μMNADH/NAD+ ratio
No drug0.95 ± 0.110.3 ± 0.030.32 ± 0.01
Thioridazine (40)0.72 ± 0.080.39 ± 0.040.54 ± 0.11*
Thioridazine (80)0.66 ± 0.04*0.56 ± 0.11*0.85 ± 0.22*
Rifampicin (1)0.90 ± 0.030.37 ± 0.030.41 ± 0.05
R207910 (5)0.99 ± 0.030.38 ± 0.040.38 ± 0.05
R207910 (10)1.16 ± 0.020.37 ± 0.020.31 ± 0.02
  • Hypoxic nonreplicating Mtb H37Rv was incubated with the ndh-2 inhibitor thioridazine for 3 h under anaerobic conditions before quantification of the [NADH]/[NAD+] ratio. The compounds were used at 2- and 4-fold of the WCC90 concentration for thioridazine and R207910 and at 2-fold the WCC90 concentration for rifampicin. The experiments were carried out three times in triplicate; one of the representative experiments is shown with means and standard deviations.

  • *Mean values are statistically different (P < 0.05) compared with the mean values of the no-drug-treated Mtb cells.